Inteb (Budesonide)

Budesonide acts locally in the gastrointestinal tract to manage inflammatory bowel disease.

• Crohn's disease: reduces intestinal inflammation and induces remission in affected segments.
• Ulcerative colitis: alleviates colonic inflammation and promotes mucosal healing.
• Inflammatory bowel disease (IBD): provides targeted glucocorticoid therapy to control disease activity and symptoms.

• Budesonide binds to intracellular glucocorticoid receptors, altering gene transcription that suppresses pro‑inflammatory cytokines, chemokines, and adhesion molecules. This modulation decreases leukocyte infiltration and edema in the intestinal mucosa, resulting in potent local anti‑inflammatory and immunosuppressive effects with limited systemic exposure.

Budesonide may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate pain often transient.
• Nausea: occasional upset stomach or queasiness.
• Abdominal pain: cramping or discomfort in the gut.
• Dyspepsia: indigestion or heartburn.
• Insomnia: difficulty falling or staying asleep.
• Increased appetite: heightened hunger leading to weight change.

Serious or Rare Side Effects

• Adrenal suppression: reduced endogenous cortisol production.
• Severe infections: heightened risk of bacterial, viral, or fungal infections.
• Hypersensitivity reactions: rash, urticaria, or anaphylaxis.
• Osteoporosis: decreased bone mineral density with long‑term use.
• Cataracts: clouding of the eye lens.
• Severe gastrointestinal bleeding: ulceration or hemorrhage.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

• Infection monitoring: assess for signs of new or worsening infections.
• Adrenal function: evaluate cortisol levels if long‑term therapy is planned.
• Dose minimization: use the lowest effective dose for the shortest duration.
• Discontinuation: avoid abrupt cessation; taper as advised by a physician.
• Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Budesonide may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase systemic exposure.
• Systemic antifungal agents (e.g., fluconazole): may raise budesonide levels.
• Ritonavir (HIV protease inhibitor): can markedly elevate plasma concentrations.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): reduce therapeutic effect.
• Oral contraceptives: possible reduction in contraceptive efficacy.
• NSAIDs: heightened risk of gastrointestinal irritation or ulceration.
• Diuretics: may exacerbate electrolyte imbalances.
• Live vaccines: immunogenic response may be diminished.